Why Regeneron Shares Are Falling Today

Regeneron Pharmaceuticals (REGN) is down 3.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The pullback appears tied to a mix of existing pressure around Regeneron’s Eylea franchise and investor caution ahead of second-quarter results due July 30, 2026. This could also reflect digestion of the company’s recent disclosure that second-quarter results will include an acquired in-process R&D charge, which may be adding to near-term earnings sensitivity.

Details:

Regeneron disclosed in a July 6 Form 8-K that second-quarter 2026 results are expected to include an acquired in-process research and development charge of about $127 million before tax.

The company has already scheduled its second-quarter 2026 earnings release for July 30, leaving the stock vulnerable to pre-earnings repositioning.

Recent market commentary has highlighted continued concern about the Eylea business, even as Eylea HD has won important label expansions and dosing flexibility approvals in 2026.

Regeneron’s first-quarter 2026 update showed U.S. Eylea sales declining year over year, reinforcing investor focus on whether newer Eylea HD growth can offset pressure in the legacy franchise.

Sources:

SEC, Regeneron Pharmaceuticals, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$REGN Insider Trading Activity

$REGN insiders have traded $REGN stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales.

Here’s a breakdown of recent trading of $REGN stock by insiders over the last 6 months:

JASON PITOFSKY (SVP Controller) has made 0 purchases and 11 sales selling 2,036 shares for an estimated $1,585,058.
HUDA Y ZOGHBI has made 0 purchases and 11 sales selling 1,638 shares for an estimated $1,279,811.
ARTHUR F RYAN has made 0 purchases and 26 sales selling 400 shares for an estimated $278,406.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive REGN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$REGN Hedge Fund Activity

We have seen 586 institutional investors add shares of $REGN stock to their portfolio, and 570 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP added 1,172,994 shares (+176.5%) to their portfolio in Q1 2026, for an estimated $898,970,871
FMR LLC removed 801,374 shares (-34.5%) from their portfolio in Q1 2026, for an estimated $614,165,019
TWO SIGMA INVESTMENTS, LP added 531,085 shares (+188.9%) to their portfolio in Q1 2026, for an estimated $407,018,233
MARSHALL WACE, LLP removed 478,198 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $366,486,165
HOLOCENE ADVISORS, LP removed 460,723 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $353,093,499
MILLENNIUM MANAGEMENT LLC removed 317,038 shares (-83.5%) from their portfolio in Q1 2026, for an estimated $242,974,752
ACADIAN ASSET MANAGEMENT LLC removed 294,604 shares (-66.1%) from their portfolio in Q1 2026, for an estimated $225,781,559

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$REGN Congressional Stock Trading

Members of Congress have traded $REGN stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 05/15.
SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
REPRESENTATIVE JULIA LETLOW purchased up to $15,000 on 02/12.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$REGN Analyst Ratings

Wall Street analysts have issued reports on $REGN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HSBC issued a "Buy" rating on 07/06/2026
Barclays issued a "Overweight" rating on 04/30/2026
Truist Securities issued a "Buy" rating on 04/30/2026
Cantor Fitzgerald issued a "Overweight" rating on 02/02/2026

To track analyst ratings and price targets for $REGN, check out Quiver Quantitative's $REGN forecast page.

$REGN Price Targets

Multiple analysts have issued price targets for $REGN recently. We have seen 18 analysts offer price targets for $REGN in the last 6 months, with a median target of $809.5.

Here are some recent targets:

Biren Amin from Piper Sandler set a target price of $854.0 on 07/09/2026
Matthew Harrison from Morgan Stanley set a target price of $730.0 on 07/08/2026
Gregory Renza from Truist Securities set a target price of $769.0 on 07/07/2026
Brian Abrahams from RBC Capital set a target price of $696.0 on 07/07/2026
Robert Wasserman from Benchmark set a target price of $185.0 on 07/07/2026
Carter Gould from Cantor Fitzgerald set a target price of $750.0 on 07/06/2026
Rajesh Kumar from HSBC set a target price of $880.0 on 07/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.